PBLA News and Press, Panbela Therapeutics Inc Com From 04/30/24

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthes...

2024-04-22 09:18:37 ET More on Panbela Therapeutics Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript Panbela Therapeutics closes ~$9M public offering of shares Panbela Therapeutics drops on $9M public offering Seeking Alpha’s Quant Ra...

MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ...

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved...

2024-03-26 21:49:10 ET Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Conference Call March 26, 2024 04:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer C...

2024-03-26 16:14:50 ET More on Panbela Therapeutics Panbela Therapeutics closes ~$9M public offering of shares Panbela Therapeutics drops on $9M public offering Seeking Alpha’s Quant Rating on Panbela Therapeutics Historical earnings data for Panbela T...

MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on...

2024-02-15 09:22:43 ET More on Panbela Therapeutics Panbela Therapeutics closes ~$9M public offering of shares Panbela Therapeutics drops on $9M public offering Seeking Alpha’s Quant Rating on Panbela Therapeutics Read the full article on Seeking Alp...